Clinical commissioning policy: intravenous (6 years and above) and subcutaneous (adolescents and adults) C1 esterase inhibitor injections for routine prophylaxis of hereditary angioedema type I and II or acquired angioedema

Document first published:
Page updated:
Topic:
Publication type:

This policy was first published in 2016. The updated version reflects changes in product availability and references alternative treatment options and changes in product licenses affecting patient age and route of administration.

Document

Clinical commissioning policy: intravenous (6 years and above) and subcutaneous (adolescents and adults) C1 esterase inhibitor injections for routine prophylaxis of hereditary angioedema type I and II or acquired angioedema

Clinical commissioning policy: intravenous (6 years and above) and subcutaneous (adolescents and adults) C1 esterase inhibitor injections for routine prophylaxis of hereditary angioedema type I and II or acquired angioedema

  • PDF
  • 406 KB
  • 12 pages

Summary

Updated version published April 2026.

Document

Commissioned treatment options for patients with hereditary angioedema secondary to C1 esterase inhibitor deficiency algorithms

Commissioned treatment options for patients with hereditary angioedema secondary to C1 esterase inhibitor deficiency algorithms

  • PDF
  • 243 KB
  • 4 pages

Summary

This algorithm was first published in February 2025. The updated version, published in April 2026, reflects the availability of new treatments such as garadacimab, and NHS England’s updated C1-esterase inhibitor prophylaxis policy. In addition, the presentation of the algorithms has been updated to make them easier to understand, and additional information is included to further assist clinicians with decision making and commissioning policy compliance.